ClinicalTrials.gg
Status unknownNCT04949880Updated Oct 17, 2022

A Single-Arm Trial of Neurovascular Drug-Eluting Balloon Dilatation Catheter Treating Symptomatic Intracranial Atherosclerotic Stenosis

An interventional study of Neurovascular Drug-Eluting Balloon Dilatation Catheter in Intracranial Atherosclerosis, sponsored by Zhejiang Zylox Medical Device Co., Ltd.. Status unknown at 11 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-10-17.

Sponsored by Zhejiang Zylox Medical Device Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Intracranial Arteriosclerosis with a site in China — 28 open to participants now, 28 under way, 2 of them phase 3. Intracranial Arteriosclerosis · China.

Planned enrollment
22nd of 27
132 · median 200
Started
2021
with 4 others
No phase
16 of 44
8 open now
Registered
15th of 44
by date

Among the 44 studies in Intracranial Arteriosclerosis with a site in China, this one is the 22nd largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2021, is one of 16 with no phase, and was the 15th registered.

Intracranial Arteriosclerosis

103 studies on the registry are indexed under Intracranial Arteriosclerosis; 49 are open to participants now.

Browse Intracranial Arteriosclerosis studies →

Open to participants now

28 of the 44 studies in Intracranial Arteriosclerosis with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Intracranial Arteriosclerosis studies recruiting now, 12 (41%) set no upper age limit and 1 (3%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Intracranial Arteriosclerosis with a site in China, or all of them as a file.
02

Study summary

This is a trial designed to test the efficacy and safety of the Neurovascular Drug-Eluting Balloon Dilatation Catheter.

Read the detailed description

This is a prospective multicentre single-arm trial conducted by 11 centers in mainland China. Approximately 132 subjects with symptomatic intracranial atherosclerotic stenosis receive endovascular treatment using the neurovascular drug-eluting balloon dilatation catheter designed by Zylox.

03

Conditions studied

  • Intracranial Atherosclerosis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 80 years, any gender;
  • Subject has symptomatic intracranial atherosclerotic stenosis that the degree of the artery stenosis is between 70% and 99% diagnosed by intracranial angiography;
  • The target stenotic artery locates in Internal Carotid Artery (intracranial segment), Middle Cerebral Artery (M1, M2), Basilar Artery, Vertebral Artery (intracranial segment);
  • Intracranial artery stenosis requiring interventional treatment is a single lesion;
  • Subject has at least two atherosclerosis risk factors including history or present hypertension, diabetes, hyperlipidemia, smoking, age>45;
  • modified Rankin Scale(mRS) score≤2 before enrollment;
  • Subject or guardian is able to understand the purpose of study, agree to provide follow-up data and has provided written .

Exclusion criteria

Exclusion Criteria:

  • History of acute ischemic stroke within 2 weeks;
  • History of intracranial hemorrhage (including intraparenchymal hemorrhage, subarachnoid hemorrhage, subdural hemorrhage and epidural hemorrhage) within 3 months;
  • Hypertension uncontrolled by medicine (Systolic pressure≥180 mmHg or diastolic pressure≥110 mmHg continuously);
  • Combined with the intracranial tumor, aneurysm or intracranial arteriovenous malformation;
  • The length of intracranial artery stenosis >10mm and extremely angulated >90°, which indicated by angiography;
  • History of stent intervention within the target lesion;
  • Allergic to heparin, sirolimus (i.e. rapamycin), contrast agents, aspirin, clopidogrel, anesthetics;
  • History of gastrointestinal hemorrhage within 6 months before signing the form, which is unable to receive antiplatelet therapy;
  • (PLT)\<90*10\^9/L;
  • Creatinine>250 umol/L;
  • (INR)>1.5;
  • Female subject who is pregnant or breast-feeding, or who has a pregnancy plan within 12 months;
  • Expected life \<12 months;
  • Unable to cooperate with or tolerate the interventional surgery;
  • Subject who has participated in other drug or device clinical trials or hasn't reached the primary end point;
  • Angiography indicates intracranial artery stenosis caused by arterial dissection, arteritis, and thrombosis;
  • Angiography indicates the vascular path is tortuous, the experimental device is difficult to reach the target position or be retracted;
  • Other circumstances judged by researchers that are not suitable for enrollment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Group A

    Neurovascular Drug-Eluting Balloon Dilatation Catheter

    Device: Neurovascular Drug-Eluting Balloon Dilatation Catheter

Interventions

  • DeviceNeurovascular Drug-Eluting Balloon Dilatation Catheter

    The neurovascular drug-eluting balloon dilatation catheter consists of a tip, a drug-coated balloon, markers, a catheter and a catheter hub. The main component of the drug coating is sirolimus, and the coating is evenly distributed on the effective length surface of the balloon.

06

What researchers measure

Primary outcomes

  1. Restenosis rate of the target lesion

    Subjects receive Digital Subtraction Angiography (DSA) / Computed Tomography Angiography (CTA) examination in 180 days to analyze whether the degree of stenosis is greater than or equal to 50%, if so, the target lesion restenosis happens.

    Time frame: 180+60 days

Secondary outcomes

  1. Average stenosis degree of the target lesion

    Subjects receive DSA / CTA examination in 180 days.

    Time frame: 180+60 days

  2. Success rate of device

    After receiving DSA examination, success rate of device is defined as experimental device-neurovascular drug-eluting balloon dilatation catheter advanced on position successfully, balloon retracted smoothly after expanded, without balloon rupture and balloon catheter break, etc.

    Time frame: Intraoperation

  3. Success rate of surgery

    After receiving DSA examination, success rate of surgery is defined as the final residual stenosis degree of target lesion\<50% and modified thrombolysis in cerebral infarction score (mTICI) 2b/3, whether or not other additional treatments are applied.

    Time frame: Intraoperation

Other outcomes

  1. Incidence of device deficiency

    Device deficiency is the unreasonable risk that may endanger human health and life safety in the normal use of medical devices during clinical trials, such as labeling errors, quality problems, malfunctions, etc.

    Time frame: within 180+60 days

  2. Incidence of stroke events

    Stroke events include hemorrhagic or ischemic stroke, transient cerebral ischemia.

    Time frame: 7 days or at discharge / 30±7 days / 180+60 days

  3. Rate of death

    Subjects who died from any cause would be counted.

    Time frame: 7 days or at discharge / 30±7 days / 180+60 days

  4. The rate of AE

    The definition of AE (Adverse Event) refers to ISO 14155.

    Time frame: within 180+60 days

  5. The rate of SAE

    The definition of SAE (Serious Adverse Event) refers to ISO 14155.

    Time frame: within 180+60 days

07

Study locations

11 sites
  • The First Affiliated Hospital of USTC
    Hefei, Anhui, China
  • The First Affiliated Hospital of Wannan Medical College
    Wuhu, Anhui, China
  • Cangzhou Central hospital
    Cangzhou, Hebei, China
  • Wuhan Hospital of Traditional Chinese and Western Medicine
    Wuhan, Hubei, China
  • General Hospital of Northen Theater Command
    Shenyang, Liaoning, China
  • Linyi People's Hospital
    Linyi, Shandong, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, Shandong, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, China
  • Xuanwu Hospital Capital Medical University
    Beijing, China
  • Changhai Hospital of Shanghai
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for May 2023, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
Jul 2, 2021
StartActual
Nov 2, 2021
Primary completionEst.
May 2023
CompletionEst.
May 2023
Last update
Oct 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04949880
Lead sponsor
Zhejiang Zylox Medical Device Co., Ltd.
Responsible party
Sponsor
First posted
Jul 2, 2021
Start date
Nov 2, 2021
Primary completion
May 2023 (estimated)
Completion
May 2023 (estimated)
Last update
Oct 17, 2022

Study contacts

Jianmin Liu
principal investigator · Changhai Hospital
Liqun Jiao
principal investigator · Xuanwu Hospital, Beijing

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion